Industry / Finland

Coping With Spiralling Drug Costs

June 2008 | Industry News

Printable version
Bookmark

A new report from the London School of Economics assessing the pharmaceutical policies in Finland has identified a number of challenges and possible methods for overcoming rising drug expenditure in the country.

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Orion Revenues Increase Despite A Difficult Business Environment In Its Primary Market

Industry / Finland BMI Core View: The long-term value of any pharmaceutical company will be driven by maintaining internal research and development (R&D) productivity to ensure a steady rate of product launches, with...

June 2011

Government's Contribution To Health Expenditure Forecast To Decline

Industry / Finland In 2008, Finnish health expenditure reached EUR14.9bn (US$21.9bn) and by 2009 it is expected to top EUR15.4bn. However, as a result of the weakening euro, health expenditure in US dollar terms will decline...

November 2009

Healthcare And Life Sciences Sectors Witness Rapid Growth

Industry / Finland News: The Finnish healthcare and life sciences sectors have witnessed a very rapid growth in recent years, reports Engineering News. Basic research in enzymes and drug discovery has helped to develop highly...

June 2009

Cerepro Approved On A Named Patient Basis

Industry / Finland Finland's National Agency for Medicines has approved Ark Therapeutics' Cerepro (sitimagene ceradenovec) on a named patient basis. The drug is a novel gene-based therapy, developed as an orphan drug,...

May 2009

Growth In Drug Reimbursements Remain Under 5% As Budgeted

Industry / Finland In 2008, expenditure on the reimbursement of medicines in Finland increased to EUR1.24bn (US$1.68bn), equating to an 8.8% rise in value from 2007. Additionally, sales of reimbursed drugs reached EUR1.17bn...

May 2009